Company intelligence / Profile preview

Ador Diagnostics

Rome, Italy

Ownership: Private
Development stage: Other

Overview

Ador Diagnostics' NATlab platform is undergoing pre-clinical trials in collaboration with hospitals; it has demonstrated the ability to rapidly and accurately identify over 100 pathogens/targets per run with results in 30–45 minutes, enabling rapid point-of-care diagnosis for infectious diseases.[1][2][3]

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic PanelMicrofluidic CartridgeRolling circle amplification assay
Industry: Molecular Diagnostics

Partnerships

BATM Advanced Communications (major strategic and financial partner)[3]

Beyond the preview

Go deeper on Ador Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ador Diagnostics.

Explore the full profile